Test Before Treat
Where you start your CLL journey matters.
How you live is everything.
The Challenge
Too many CLL/SLL patients are not receiving the therapies that may work best for them based on their unique biomarker profile.
Why It Matters
Approximately 50% of newly diagnosed CLL patients have high-risk features that put them at higher risk for disease progression and poor outcomes—especially when treatment is not selected based on the most favorable evidence for use with their unique genetic subsets. Biomarker testing at diagnosis and re-testing at each disease progression is critical to ensure every patient gets the best treatment at each stage of their disease.
What We’re Doing
As a company dedicated to putting patients first, BeOne Medicines USA has partnered with CLL Society to power Test Before Treat, a campaign that educates healthcare professionals and patients living with CLL/SLL about the importance of biomarker testing before initial treatment and retesting before each subsequent treatment as some biomarkers evolve over time with high-risk refractory disease becoming more common. Early testing can help predict how aggressive the disease may act and how to best treat it based on a patient’s unique biomarker status, because achieving the best outcome is everything.
Who It Impacts
Everyone. All CLL/SLL patients need to understand their mutations and know their risk status for disease progression and outcomes.
Hear more about this directly from Nathan, a 52-year-old CLL patient whose life was changed through biomarker testing.
